Update: Canadian Drug Agency Funding Success for Pulmonary Hypertension Research

Great news for the Pulmonary Hypertension (PH) community! Through the Canadian Drug Agency's (CDA) funding initiative for rare diseases, the Canadian PH Registry has been awarded $101,026 to support critical research and data collection. This funding call, which took place in March, was part of an effort to improve access to innovative treatments and advance outcomes for those living with rare conditions, including PH.

The PH Registry’s funding marks a significant step forward. By supporting research and comprehensive data collection, we’re closer to a future with better treatments and improved care for Canadians with PH. If you’re a researcher, healthcare provider, or organization involved in rare disease work, stay tuned for future funding opportunities from the CDA to drive further progress.

Learn more about this initiative and the impact it has on rare disease communities: CDA Rare Disease Funding Opportunity..

Together, we’re making strides toward meaningful advancements for the PH and rare disease communities across Canada!